According to filings with the U.S. Securities and Exchange Commission, Biofrontera is raising $8,000,000.00 in new funding. About Biofrontera: Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Our vision at Biofrontera Inc. is to be a trusted partner who brings unparalleled therapies and service to patients and healthcare providers in the dermatology community. Biofrontera Inc. will become a leading U.S. specialty dermatology company by focusing on innovative therapy options that enable dermatology healthcare professionals to help improve the lives of their patients.

To learn more about Biofrontera, visit http://www.biofrontera-us.com/

Contact:
Hermann Luebbert, Chief Executive Officer
781-245-1325

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.